Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis
- PMID: 38382595
- DOI: 10.1016/j.jtho.2024.02.006
Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis
Abstract
Introduction: The International Agency for Research on Cancer has classified passive smoking (PS) or secondhand smoke exposure as a group 1 carcinogen linked to lung cancer. However, in contrast to active smoking, the mutagenic properties of PS remain unclear.
Methods: A consecutive cohort of 564 lung adenocarcinoma samples from female never-smokers, who provided detailed information about their exposure to PS during adolescence and in their thirties through a questionnaire, was prepared. Of these, all 291 cases for whom frozen tumor tissues were available were subjected to whole exome sequencing to estimate tumor mutational burden, and the top 84 cases who were exposed daily, or not, to PS during adolescence, in their thirties or in both periods, were further subjected to whole genome sequencing.
Results: A modest yet statistically significant increase in tumor mutational burden was observed in the group exposed to PS compared with the group not exposed to PS (median values = 1.44 versus 1.29 per megabase, respectively; p = 0.020). Instead of inducing driver oncogene mutations, PS-induced substantial subclonal mutations exhibiting APOBEC-type signatures, including SMAD4 and ADGRG6 hotspot mutations. A polymorphic APOBEC3A/3B allele-specific to the Asian population that leads to up-regulated expression of APOBEC3A accentuated the mutational load in individuals exposed daily to PS during adolescence.
Conclusions: This study reveals that PS-induced mutagenesis can promote lung carcinogenesis. The APOBEC3A/3B polymorphism may serve as a biomarker for identifying passive nonsmoking individuals at high risk of developing lung cancer.
Keywords: APOBEC; Lung adenocarcinoma; Mutational signature; Passive smoking; Polymorphism.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Disclosure Dr. Yatabe reports receiving grants from ArcherDx, Chugai- Pharma, Thermo Fisher Science, Konica Minolta REALM, Otsuka Pharma, NEC Corporation, AstraZeneca, Merk Biopharma, Johnson&Johnson and Public Health Research Foundation; receiving honoraria for advisory board or lectures from AbbVie Inc., Amgen, Bayer, Daiichi-Sankyo, Merck Bio-Pharma, MSD, Novartis, AstraZeneca, Aglient/Dako, Chugai-Pharma, Janssen-Pharma, Takeda, Ono Pharma, Elilliy and ACE Oncology; and having participation on advisory boards of MSD, Chugai- Pharma, AstraZeneca, Novartis, Amgen, Takeda, Daiichi-Sankyo, Janssen-Pharma and Merk-Biopharma. Dr. Hamamoto reports receiving grants from Japan Science and Technology Agency CREST and AIP-PRISM. Dr. Kohno reports receiving grants from The Japan Agency for Medical Research and Development.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous